Given that classic targets, such as the p53 and retinoblastoma pathway and EGFR targeted therapy, have failed to provide clinical benefit in patients with glioma, new potential strategies are currently focusing on immunotherapy, tumor microenvironment, and a combination of several efficacious methods [42]. This evidence concerns the gene EGFR and glioma.